Winship Cancer Institute, Emory University Atlanta, Georgia
Multiple Myeloma (MM), a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy induction, plus or minus an autologous stem cell transplant (ASCT) as consolidation, which is then followed by maintenance therapy. This session will aim to highlight the data surrounding utilization of an early or delayed ASCT, as well as the role of the ASCT now that novel therapies such as daratumumab and carfilzomib are being introduced in the induction setting. We will discuss the role of the pharmacist in the care of patients with myeloma and management of adverse events. We will analyze complex patient cases and treatment approaches based on patient-specific characteristics, biomarkers, efficacy and safety data, and cost.
Learning Objectives:
Analyze the current literature surrounding the utilization of autologous stem cell transplant (ASCT) for Multiple Myeloma
Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for ASCT in Multiple Myeloma
Select appropriate prevention and monitoring strategies to address complications and toxicities and optimize treatment outcomes associated with ASCT in Multiple Myeloma